Released on = August 1, 2007, 8:12 pm

Press Release Author = Jon Bradshaw

Industry = Biotech

Press Release Summary = Theravitae has announced a viable third option instead of
death or transplant for heart attack patients whose heart has been severely damaged
and is failing. They cite the case of Terry Areford from Morgantown, West Virginia
who declined both of what he believed were his only options and instead chose the
realistic hope of help from his own adult stem cells.

Press Release Body = BANGKOK, Thailand, August 1, 2007 - Heart disease, according to
the figures from The National Center for Health Statistics 2005 data, affects some
25.6 million Americans. It was then, and remains, the biggest killer of U.S.
citizens, with over 650,000 dying every year. Until now as patients deteriorated and
medication or surgery on their heart failed to help they were faced with only two
options, a heart transplant or death.

Theravitae, an international biotechnology company based in Thailand, claim they can
provide a realistic third option that offers new hope to heart failure patients -
treatment with their own adult stem cells. Their patented therapy, VesCell, uses a
mere half pint of the patient's own blood which is sent to their laboratory where
the therapeutic stem cells are multiplied by millions and then injected directly or
implanted by catheter into the damaged heart muscle or occluded heart blood vessels.
Hundreds of their patients have attested to the fact that their lives have been
improved and lengthened by this technique which is performed by cardiac specialists
in world-class hospitals in Thailand.

Terry Areford from Morgantown, West Virginia is just one patient who was not told by
his cardiologist that the option of adult stem cell therapy existed for him. More
appalling than not being so advised, he was a patient at the prestigious teaching
hospital attached to the University of West Virginia where he could reasonably have
expected to receive the best and most advanced treatment options available to
medical science. He believed that his imminent death was unavoidable because he did
not want a transplant and after several heart attacks, six bypasses and more than
half a dozen operations to insert stents he had only one small vessel left pumping
blood to the front of his heart.

Daily living for Terry was characterized by pain and shortness of breath. He could
not walk a hundred feet without tightness in his chest and at only 60 years of age
felt that he would like to be around a little longer to enjoy his family and
grandchildren. He was upset and felt that there ought to have been more that could
be done to help him. Fortunately for him his daughter was internet savvy and
searched until she found that there was, indeed, grounds for hope.

'I think it's a total shame that I cannot get the help I need at home. I found out
that there is some research going on with adult stem cells in the U.S. but they are
like five year trials. I couldn't wait five years. There's going to be a lot of
people dead in five years and they wouldn't have to be dead if they knew about adult
stem cell therapy,' he said.

'I hope ten people read my story and go out and tell ten more people so that
everybody comes to understand what this is all about. I was using my own body to
help, or perhaps cure, my own body. There is no rejection factor and it took only a
small incision in my chest wall and an injection of my own stem cells into the
heart. Once implanted these cells do what they are programmed to do - revascularize
to improve blood flow to my useless heart muscle. While my wife shopped and visited
the temples and markets I lay back in a superb hospital with fantastic care to get
well,' he added.

About TheraVitae:
TheraVitae is a private, multinational company focused on using stem cells from the
patient\'s own blood in order to treat a variety of disorders, especially
cardiovascular diseases. The company has developed a proprietary stem cell
technology, \'VesCell\', that is currently being used by hospitals in Thailand and
Singapore to treat patients with heart disease and peripheral artery disease.
VesCell -- A Natural Treatment for Heart Disease and Peripheral Arterial Disease (PAD)
The body has natural ways of healing itself and the cardiovascular system is no
exception. Angiogenic Cell Precursors (ACPs) originate in bone marrow and then
circulate in the blood vessels. To manufacture VesCell, TheraVitae expands a small
number of ACPs harvested from about 250cc of blood into a therapeutic quantity.
VesCell is injected either through a coronary artery via catheter, or during
surgery, directly into the heart muscle.
A key aspect of VesCell therapy is the advanced cell isolation and expansion
technique that allows for the ACPs to be harvested from blood collected in a
procedure similar to a common blood donation. VesCell uses a patient\'s own adult
stem cells to treat Heart Disease and PAD and is a viable therapeutic possibility
for heart or PAD patients without any other treatment option.
TheraVitae Corporate Web Site: http://www.theravitae.com
VesCell Web Site: http://www.vescell.com



Web Site = http://VesCell.com

Contact Details = 36/72 P.S. Tower, Sukhumvit 21, Klongtoey-Nua, Wattana. Bangkok
10110, Thailand.
+66 2664 4290
Email: jon@theravitae.com